Connor Clark & Lunn Investment Management Ltd. reduced its stake in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Free Report) by 15.9% in the fourth quarter, according to the company in its most ...

HC Wainwright reissued their buy rating on shares of PMV Pharmaceuticals (NASDAQ:PMVP – Free Report) in a report released on Thursday morning,Benzinga reports. The firm currently has a $5.00 target ...

This marks Jacobio's successful transformation from the early R&D stage to an innovation-driven value realization stage," said Dr.Yinxiang Wang, the Chairman and CEO of Jacobio Pharma. "Looking ahead ...

The paper titled,“Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development” can be accessed here . Announced a partnership with ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ... therapies targeting p53, today reported ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced ... tumor-agnostic therapies ...

Researchers from PMV Pharmaceuticals Inc. and collaborators described the effect of rezatapopt (PC-14586), a first-in-class selective p53 reactivator designed to reinstate p53 Y220C mutant function.

PC14586, a novel small-molecule p53 reactivator, selectively binds to a specific pocket in the TP53 Y220C mutant protein, aiming to restore the conformation and transcriptional activity of wild-type ...

MANILA – The Philippine Economic Zone Authority (Peza) has approved P52.93 billion worth of investment pledges in the first two months of the year. PEZA reported Tuesday that its investment ...

Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney ...